CAMP Projects

Projects within CAMP cover scientific, technological and infrastructure challenges around process development and production of ATMP.

Twenty collaboration projects engaging partners from healthcare, industry and academy have been, or are currently running within CAMP. Find links to partner websites.

Current project portfolio

Automated manufaturing of ATMPs project page

Project leader: Malin Parmar, Lund University 

Project partners: Lund University, Skåne University Hospital, Miltenyi Biotec 

Development of Multilayered Tissue-Engineered Skin Construct project page

Project leader: Folke Sjöberg, Region Östergötland 

Project partners: Region Östergötland, Region Västerbotten, Umeå University, Cellastra, VivaBioCell, Xintela  

GMP production of pluripotent stem cells and its derivatives project page

Project leader: Anders Lindahl, University of Gothenburg 

Project partners: University of Gothenburg, Karolinska Institutet, Umeå University, Region Västerbotten, Vecura/Karolinska Universitetssjukhuset, Takara Bio Europe, VERIGRAFT 

Extracellular vesicles (CARMEV) for prevention of heart failure project page

Project leader: Karl-Henrik Grinnemo, Akademiska Sjukhuset 

Project partners: Akademiska sjukhuset, Uppsala University, AstraZeneca, Mitosense  

Personalised ATMP for the regeneration of arteries project page

Project leader: Joakim Håkansson, RISE Research Institutes of Sweden 

Project partners: RISE, University of Gothenburg, Västra Götalandsregionen, VERIGRAFT, Your Special Delivery Service 

Fully closed (from vein to vein) and automated CAR-T manufacturing process project page

Project leader: Di Yu, Uppsala University 

Project partners: Uppsala University, Vecura/Karolinska University Hospital, Elicera Therapeutics 

Amniotic derived cell therapy improving outcome in lung transplantation project page

Project leader: Sandra Lindstedt, Skåne University Hospital 

Project partners: Skåne University Hospital, Lund University, Amniotics 

GMP-compliant infrastructure and production in a hospital-setting of mesenchymal stromal cells from lipoaspirate for use in clinical trials project page

Project leader: Peter Tropp, Region Örebro län 

Project partners: Region Örebro län, Region Västerbotten, Acousort, VivaBioCell 

Pre-GMP development of ATMPs and other gene-based strategies project page

  • Subproject 1. GMP education and training courses focused on ATMPs
  • Subproject 2. Development of HQ plasmid production link
  • Subproject 3. Development of small-medium scale viral vector production
  • Subproject 4. Development of genetically modified T cells (extension of ongoing project)
  • Subproject 5. Multi-use RNA production platform for A/GTMPs, and other gene-based interventions

Project leader: Matti Sällberg, Karolinska Institutet 

Project partners: Karolinska Institutet, Vecura(Karolinska University Hospital, Lund University, Umeå University, Uppsala University, Region Västerbotten, Cytiva, Key2Compliance, NorthX Bio, SVF Vaccines 

 Vecura/KCC – an infrastructure for manufacturing of ATMPs project page

  • Subproject 1. Expansion of GMP Compliant Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor – link
  • Subproject 2. Expansion of GMP-compliant adaptive T-cells in bioreactor
  • Subproject 3. Cell processing of NK-cells using Sepax cell processing instrument

Project leader: Pontus Blomberg, Vecura/Karolinska University Hospital 

Project partners: Vecura/Karolinska University Hospital, Karolinska Institutet, Cytiva, NEOGAP, XNK Therapeutics 

Completed projects

  1. Scaleable magnetic isolation of differentiated stem cells
  2. QC and logistics
  3. Label-free sorting of stromal cell preparations for clinical use
  4. ATMP for urethra reconstruction with de- and recellularization technique
  5. CAR-T cell therapy for malignant melanoma of the skin and the eye
  6. Value survey – How do donors, patients, the general public and policy makers want to balance different interests?
  7. Development of producer lines for delivering therapeutic mRNAs through Extracellular Vesicles
  8. Single cell qPCR characterization of ATMP
  9. Establishing a non-dry ice dependent logistics strategy for cell therapies
  10. Establishing a QC and logistics strategy of cell-based products for secure patient treatment.